Contineum Therapeutics has concluded targeted enrolment in a Phase II trial of PIPE-307 for relapsing-remitting multiple sclerosis (RRMS).

The Phase III trial successfully saw patients achieving clinical remission and stopping rectal bleeding within 28 days.

MaaT Pharma has seen its microbiome therapy for patients living with treatment-induced dysbiosis hit its endpoints.

Viking Therapeutics has begun a Phase II clinical trial of VK2735 aimed at treating metabolic disorders, such as obesity.

Suven Life Sciences has announced the dosing of the first subjects in its Phase I clinical trial of SUVN-I6107 to treat cognitive disorders.

Cervical cancer begins in the cells of the cervix and is primarily caused by the human papillomavirus (HPV), a common sexually transmitted virus.